Individualised incretin-based treatment for type 2 diabetes.
Nauck
Michael A
MA
Diabeteszentrum Bad Lauterberg, D-37431 Bad Lauterberg im Harz, Germany. nauck@diabeteszentrum.de
Meier
Juris J
JJ
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D054795:Incretins / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008687:Metformin / Q000008:administration & dosage; D010455:Peptides / Q000008:administration & dosage; D000077205:Pioglitazone; D011719:Pyrazines / Q000008:administration & dosage; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage; D014688:Venoms / Q000008:administration & dosage
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D011719:Pyrazines; D045162:Thiazolidinediones; D014230:Triazoles; D014688:Venoms; D000069036:Insulin Glargine; D008687:Metformin; D000077270:Exenatide; D000068900:Sitagliptin Phosphate; D000077205:Pioglitazone